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Abstract (3000 char)
Background: Treating prostate cancer with extraprostatic extension (stage 
T3a) or seminal vesicle invasion (stage T3b) using brachytherapy boost after 
external beam radiotherapy (EBRT) enables dose escalation and is 
technically challenging. Treatment outcomes associated with high-dose rate 
(HDR) brachytherapy boost for T3 disease have not been well described.
Objectives: Assess disease control rates among patients treated with HDR 
brachytherapy boost for T3 disease.
Methods: Retrospective chart review was performed to identify patients with 
T3 prostate cancer treated with combination EBRT and HDR brachytherapy 
boost between July 1997 and September 2014. Biochemical recurrence 
(BCR), defined as prostate specific antigen (PSA) nadir + 2 ng/mL, 
locoregional recurrence (LRR), distant metastases (DM), and prostate-cancer 
specific mortality (PCSM) were estimated using cumulative incidence and 
subdistribution hazard ratio (SHR) competing risk analysis. Overall survival 
(OS) was estimated using Kaplan Meier product limit estimator, with Cox 
proportional hazards modeling used to analyze associations between pre-
treatment characteristics and survival outcomes.
Results: Of 185 patients, 139 (75.1%) had T3a and 46 (24.9%) had T3b 
disease. Gleason 8-10 disease was present in 87 (47.3%) patients and the 
median PSA was 9.3 (interquartile range [IQR] from 25th to 75th percentile, 
5.8-19.4). Nearly all patients received whole pelvis EBRT (178, 96.2%) and 
androgen deprivation therapy (95.7%, median duration 11 months).
The median follow-up time was 89 months (IQR 49-122). The 8-year BCR rate
was 29%; 26.1% for T3a and 38.3% for T3b (SHR 1.5, 95% CI 0.9-2.7, p = 
0.15). The 8-year LRR rate was 7.9%, 5.2% for T3a and 16.8% for T3b (SHR 
2.3 95% CI 0.9-6.1, p = 0.09). The 8-year DM rate was 11.9%, 9.2% for T3a 
and 21.3% for T3b (SHR 3.0, 95% CI 1.5-6.2, p = 0.003). The 8-year PCSM 
rate was 3.6%, 1.9% for T3a and 9.1% for T3b (SHR 6.1, 95% CI 1.6-23.7, p =
0.008). The 8-year OS rate was 90.1%, 91.5% for T3a and 85.7% for T3b 
disease (Cox HR 2.1, 95% CI 0.9-4.7, p = 0.07). Grade 3 or higher 
gastrointestinal and genitourinary (GU) toxicities were rare; only one patient 
had a grade 3 chronic GU toxicity (0.6%).
Conclusions: HDR brachytherapy boost for T3 prostate cancer was well 
tolerated. Patients with T3b disease had higher rates of LRR and statistically 
significantly higher rates of DM and PCSM. This suggests HDR brachytherapy 
boost is safe and efficacious for T3 disease, but combination chemohormonal
agents may be necessary to address the high metastatic risk in patients with
locally advanced prostate cancer, particularly for T3b disease.
